Literature DB >> 27355133

Ortho-eugenol exhibits anti-nociceptive and anti-inflammatory activities.

Diogo V Fonsêca1, Paula R R Salgado2, Humberto de C Aragão Neto1, Adriana M F O Golzio2, Marcelo R D Caldas Filho1, Cynthia G F Melo1, Fagner C Leite3, Marcia R Piuvezam3, Liana Clébia de Morais Pordeus2, José M Barbosa Filho4, Reinaldo N Almeida5.   

Abstract

Ortho-eugenol is a much used phenylpropanoid whose ability to reduce pain and inflammation has never been studied. Researching ortho-eugenol's antinociceptive and anti-inflammatory activity, and its possible mechanisms of action is therefore of interest. The administration of vehicle, ortho-eugenol (50, 75 and 100mg/kg i.p.), morphine (6mg/kg, i.p.) or dexamethasone (2mg/kg, s.c.) occurred 30min before the completion of pharmacological tests. Pretreatment with ortho-eugenol did not change motor coordination test results, but reduced the number of writhes and licking times in the writhing test and glutamate test, respectively. The reaction time from thermal stimulus was significantly increased in the hot plate test after administration of ortho-eugenol. Treatment with yohimbine reversed the antinociceptive effect of ortho-eugenol, suggesting involvement of the adrenergic system. In anti-inflammatory tests, ortho-eugenol inhibited acetic acid induced vascular permeability and leukocyte migration, reducing TNF-α and IL-1β by virtue of its suppression of NF-κB and p38 phosphorylated forms in the peritonitis test. From these results, ortho-eugenol antinociceptive effects mediated by the adrenergic system and anti-inflammatory activity through regulation of proinflammatory cytokines and phosphorylation of NF-kB and p38 become evident for the first time.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-nociception; Inflammation; NF-kB; Ortho-eugenol; p38

Mesh:

Substances:

Year:  2016        PMID: 27355133     DOI: 10.1016/j.intimp.2016.06.005

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  Eugenol derivatives: synthesis, characterization, and evaluation of antibacterial and antioxidant activities.

Authors:  Francisco Felipe Maia da Silva; Francisco José Queiroz Monte; Telma Leda Gomes de Lemos; Patrícia Georgina Garcia do Nascimento; Alana Kelly de Medeiros Costa; Luanda Misley Mota de Paiva
Journal:  Chem Cent J       Date:  2018-04-03       Impact factor: 4.215

Review 2.  Analgesic-Like Activity of Essential Oil Constituents: An Update.

Authors:  Rita de Cássia da Silveira E Sá; Tamires Cardoso Lima; Flávio Rogério da Nóbrega; Anna Emmanuela Medeiros de Brito; Damião Pergentino de Sousa
Journal:  Int J Mol Sci       Date:  2017-12-09       Impact factor: 5.923

3.  Comparison study on antioxidant, DNA damage protective and antibacterial activities of eugenol and isoeugenol against several foodborne pathogens.

Authors:  Liang-Liang Zhang; Li-Fang Zhang; Jian-Guo Xu; Qing-Ping Hu
Journal:  Food Nutr Res       Date:  2017-07-18       Impact factor: 3.894

Review 4.  Nutraceuticals: Transformation of Conventional Foods into Health Promoters/Disease Preventers and Safety Considerations.

Authors:  Mudhi AlAli; Maream Alqubaisy; Mariam Nasser Aljaafari; Asma Obaid AlAli; Laila Baqais; Aidin Molouki; Aisha Abushelaibi; Kok-Song Lai; Swee-Hua Erin Lim
Journal:  Molecules       Date:  2021-04-27       Impact factor: 4.411

5.  Amino Alcohols from Eugenol as Potential Semisynthetic Insecticides: Chemical, Biological, and Computational Insights.

Authors:  Renato B Pereira; Nuno F S Pinto; Maria José G Fernandes; Tatiana F Vieira; Ana Rita O Rodrigues; David M Pereira; Sérgio F Sousa; Elisabete M S Castanheira; A Gil Fortes; M Sameiro T Gonçalves
Journal:  Molecules       Date:  2021-10-31       Impact factor: 4.411

6.  Crystal structure, Hirshfeld surface analysis and DFT studies of 1,3-bis-[2-meth-oxy-4-(prop-2-en-1-yl)phen-oxy]propane.

Authors:  Abdelmaoujoud Taia; Mohamed Essaber; Tuncer Hökelek; Abdeljalil Aatif; Joel T Mague; Ali Alsalme; Nabil Al-Zaqri
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2020-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.